This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
LogicBio Therapeutics Dirección
Dirección controles de criterios 1/4
Información clave
Fred Chereau
Chief Executive Officer (CEO)
US$2.2m
Compensación total
| Porcentaje del salario del CEO | 24.3% |
| Permanencia del CEO | 6.6yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.4yrs |
Actualizaciones recientes de la dirección
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$2m | US$543k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$2m | US$479k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$37m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$633k | US$510k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$2m | US$411k | -US$18m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$9m |
| Dec 31 2017 | US$779k | US$385k | -US$8m |
Compensación vs. Mercado: Fred's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD750.11K).
Compensación vs. Ingresos: Fred's compensation has increased whilst the company is unprofitable.
CEO
Fred Chereau (55 yo)
6.6yrs
Permanencia
US$2,228,208
Compensación
Mr. Frederic Chereau, M.B.A., also known as Fred, is the Chairman of the Board of Coave Therapeutics since October 2022 and has been its Independent Non-Executive Director since October 2021. He has execut...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.6yrs | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | no data | US$156.64k | 2.38% $ 1.6m | |
| Chief Medical Officer | 2.4yrs | US$1.54m | 0.010% $ 6.9k | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Co-Founder | 8.3yrs | sin datos | sin datos | |
| Interim CFO | less than a year | sin datos | sin datos | |
| Global VP & Head of Technology Development | 3.6yrs | sin datos | sin datos | |
| Chief Scientific Officer | 2yrs | US$1.34m | sin datos | |
| General Counsel & Corporate Secretary | 1.5yrs | sin datos | sin datos | |
| VP & Head of Human Resources | 1.2yrs | sin datos | sin datos | |
| Senior Vice President of Strategy & Portfolio Management | 1.4yrs | sin datos | sin datos | |
| Chief Business Officer | 1.3yrs | sin datos | sin datos |
1.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: LOGC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | no data | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | 6.8yrs | US$156.64k | 2.38% $ 1.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.2yrs | US$87.39k | 0.0095% $ 6.5k | |
| Independent Chairman of the Board | 4.1yrs | US$113.64k | 0.012% $ 8.1k | |
| Independent Director | 2.7yrs | US$82.02k | 0.0089% $ 6.0k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6.8yrs | US$81.14k | 0.068% $ 46.2k | |
| Independent Director | 1.9yrs | US$76.77k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$79.64k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | less than a year | US$40.31k | sin datos |
3.4yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: LOGC's board of directors are considered experienced (3.4 years average tenure).